Temozolomide significantly elevated p-4EBP1 levels in glioma cells and increased S6 phosphorylation in U251 but this was decreased in U87 and U373-U cells in contrast to the effects of mTORIs. Here, EIF4EBP1 is linked to central nervous system cancer.